SCHEMBL21247294

SCHEMBL21247294

CC(=O)N1CCC(Nc2ccc(C(=O)Nc3sc4c(c3C(=O)O)CC(C)(C)CC4(C)C)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.51
▸ PRMT5 O14744 1/20 0.41
▸ MAPT P10636 8/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ NOD1 Q9Y239 3/20 0.38
▸ TNF P01375 2/20 0.38
▸ TP53 P04637 2/20 0.37
▸ NOD2 Q9HC29 1/20 0.37
▸ RORC P51449 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ RAB7A P51149 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21250179 0.91 PTPN1 (0.53) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247277 0.89 MAPT (0.49) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247442 0.88 PTPN1 (0.55) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247169 0.87 PTPN1 (0.53) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247296 0.87 PTPN1 (0.53) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21261003 0.85 PTPN1 (0.55) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21261036 0.85 PTPN1 (0.55) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247306 0.83 PTPN1 (0.52) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247172 0.82 PTPN1 (0.50) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247337 0.79 PTPN1 (0.68) PTPN1MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH PTPN1 1639/4885PRMT5 3246/4885MAPT 2107/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH PTPN1 1639/4885PRMT5 3246/4885MAPT 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback